KRAS and non-small cell lung carcinoma: Therefore, KRAS (G12C) inhibition induced a higher rebound of phosphorylated ERK than NSCLC cells, which resulted in a generally poorer response to KRAS (G12C) inhibitors in CRC patients than in NSCLC231.